Physician profile
Bruce Gordon
NPI 1760424758
$3,771.58
in general payments reported to CMS, 2019-2025
29 companies · $660 in 2025
The $660 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,115 · 2020: $667 · 2021: $595 · 2022: $133 · 2023: $116 · 2024: $484 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.51 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $625.13 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Kala Pharmaceuticals, INC. | $547.94 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $477.73 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $280.41 | 2019-2025 | |
| Allergan, INC. | $252.74 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $215.97 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $211.62 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $147.25 | 2025 | Acthar |
| Dompe US, INC. | $102.90 | 2025 | Oxervate |
| Eyepoint US, INC. | $97.16 | 2019-2021 | |
| Oyster Point Pharma, INC. | $86.26 | 2024-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb Americas INC. | $84.09 | 2024-2025 | Miebo |
| Alimera Sciences, INC. | $83.32 | 2020-2021 | |
| Amgen INC. | $64.65 | 2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $59.24 | 2025 | Xdemvy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $58.46 | 2019-2024 | |
| Sight Sciences, INC. | $52.99 | 2019-2022 | |
| Biotissue Holdings INC. | $52.71 | 2025 | |
| Horizon Therapeutics Plc | $49.68 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $34.76 | 2019 | |
| Harrow Eye, LLC | $33.64 | 2024-2025 | Vevye |
| Coopervision INC. | $26.62 | 2022 | |
| Genzyme Corporation | $25.87 | 2019 | |
| Rxsight INC | $23.70 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Shire North American Group INC | $23.04 | 2019 | |
| Visioneering Technologies, INC. | $17.75 | 2019 | |
| Omeros Corporation | $12.50 | 2019 | |
| Alcon Research LLC | $11.77 | 2019 | |
| Spark Therapeutics, INC. | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.